Inhibitory effect of (E) -1,2-di(3,5-dimethoxyphenyl)ethene on 3T3-L1 adiopocyte differentiation

Pharmazie

Volumn 65, Issue 12, 2010, Pages 903-905

  Hwang, Jin Taek ^a   Kim, Sanghee ^b   Choi, Sang Yoon ^a  

^a Korea Food Research Institute   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DI(3,5 DIMETHOXYPHENYL)ETHENE; ACETYL COENZYME A CARBOXYLASE; FATTY ACID SYNTHASE; RESVERATROL; UNCLASSIFIED DRUG;

ADIPOCYTE; ARTICLE; CELL DIFFERENTIATION; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFECT; FATTY ACID METABOLISM; OBESITY; PROPHYLAXIS; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION;

3T3-L1 CELLS; ACETYL-COA CARBOXYLASE; ADIPOCYTES; ANIMALS; CELL DIFFERENTIATION; FATTY ACID SYNTHETASE COMPLEX; FATTY ACIDS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MICE; SPECTROPHOTOMETRY, ULTRAVIOLET; STILBENES;

EID: 78650279770     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2010.0682     Document Type: Article

References (17)

1. Adams KF, Schatzkin A, Harris TB, Kipnis V, Mouw T, Ballard-Barbash R, Hollenbeck A, Leitzmann MF (2006) Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med 355: 763-778.
2. Ahn J, Lee H, Kim S, Ha T (2007) Resveratrol inhibits TNF-α-induced changes of adipokines in 3T3-L1 adipocytes. Biochem Biophys Res Commun 364: 972-977.
3. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, Becker KG, Boss O, Gwinn D, Wang M, Ramaswarny S, Fishbein KW, Spencer RG, Lakatta EG, Couteur D, Shaw RJ, Navas P, Puigserver P, Ingram DK, Cabo R, Sinclair DA (2006) Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444: 337-342.
4. Frémont L (2000) Biological effects of resveratrol. Life Sci 66: 663-673.
5. Gnoni GV, Paglialonga G (2009) Resveratrol inhibits fatty acid and triacylglycerol synthesis in rat hepatocytes. Eur J Clin Invest 39: 211-218.
6. Horwich TB, Fonarow GC (2010) Glucose, obesity, metabolic syndrome, and diabetes relevance to incidence of heart failure. J Am Coll Cardiol 55: 283-293.
7. James PT, Rigby N, Leach R (2004) The obesity epidemic, metabolic syndrome and future prevention strategies. Eur J Cardiovasac Prev Rehabil 11: 3-8.
8. Kim JB, Sarraf P, Wright M, Yao KM, Mueller E, Solanes G, Lowell BB, Spiegelman BM (1998) Nutritional and insulin regulation of fatty acid synthetase and leptin gene expression through ADD1/SREBP1. J Clin Invest 101: 1-9.
9. Kim S, Ko H, Park JE, Jung S, Lee SK, Chun YJ (2002) Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors. J Med Chem 45: 160-164.
10. Kreuz S, Schoelch C, Thomas L, Rist W, Rippmann JF, Neubauer H (2009) Acetyl-CoA carboxylases 1 and 2 show distinct expression patterns in rats and humans and alterations in obesity and diabetes. Diabetes Metab Res Rev 25: 577-586.
11. Rayalam S, Yang JY, Ambati S, Della-Fera MA, Baile CA (2008) Resveratrol induces apoptosis and inhibits adipogenesis in 3T3-L1 adipocytes. Phytother Res 22: 1367-1371.
12. Rivera L, Morón R, Zarzuelo A, Galisteo M (2009) Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem Pharmacol 77: 1053-1063.
13. Strazzullo P, D'Elia L, Cairella G, Garbagnati F, Cappuccio FP, Scalfi L (2010) Excess Body Weight and Incidence of Stroke. Meta-Analysis of Prospective Studies with 2 Million Participants. Stroke: 41: 418-426.
14. Szkudelska K, Szkudelski T (2010) Resveratrol, obesity and diabetes. Eur J Pharmacol: 635: 1-8.
15. Tian WX (2006) Inhibition of fatty acid synthesis by polyphenols. Curr Med Chem 13: 967-977.
16. Tong I (2005) Acetyl-coenzyme A carboxylase: crucial metabolic enzyme and attractive target for drug discovery. Cell Mol Life Sci 62: 1784-1803.
17. Wakil SJ, Abu-Elheiga LA (2009) Fatty acid metabolism: target for metabolic syndrome. J Lipid Res 50: S138-S143.